This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-11. Anything still debated is marked as such rather than presented as settled.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
==== Bureaucratic/corporate operations ==== Bureaucratic/corporate organized crime groups are defined by the general rigidity of their internal structures. They focus more on how the operation works, succeeds, sustains itself or avoids retribution, they are generally typified by:
When archaic spiders moved from the water to the land in the Early Devonian period, they started making silk to protect their bodies and their eggs. Most spiders have appendages called spinnerets. These are organs that produce silk with which the spiders spin webs (although some use the silk to catch their prey in other ways). Spiders gradually started using silk for hunting purposes, first as guide lines and signal lines, then as ground or bush webs, and eventually as the aerial webs that are currently familiar. Spiders produce silk from their spinneret glands located at the tip of their abdomen. Each gland produces a thread for a special purpose – for example a trailed safety line, sticky silk for trapping prey or fine silk for wrapping it. Spiders use different gland types to produce different silks, and some spiders are capable of producing up to eight different silks during their lifetime. Most spiders have three pairs of spinnerets, each having its own function – there are also spiders with just one pair and others with as many as four pairs. Webs allow a spider to catch prey without having to expend energy by running it down, making it an efficient method of gathering food. The hair and claws on spiders' legs allow them to cling to their webs. The oils on their bodies keep them from sticking to their own webs. However these energy savings are somewhat offset by the fact that constructing the web is in itself energetically costly, due to the large amount of protein required in the form of silk.
== Principles of saw chain operation == Saw chains operate by being propelled around a guide bar, removing material from the kerf by cutting chips from the side and bottom. In order to operate properly, the depth to which each tooth cuts must be limited to avoid it binding in the wood. Scratcher chain, like the teeth on a hand saw, simply uses a multitude of teeth to prevent individual teeth from sinking too far in without undue pressure on the bar. Chipper chain, and all subsequent designs, incorporate a depth gauge (also known as a "raker") on each cutter link to limit depth of cut on each tooth. This has two distinct advantages over scratcher chain – it enables the use of fewer cutters per unit length of chain, which allows for shorter downtime for sharpening, and produces a more "open" chain layout, allowing far better clearance of chips and debris from the kerf. Individual depth gauges on each tooth also enable the use of skip chain. Skip or semi-skip chain has a further reduction in the number of teeth and is used for applications where much debris is produced, such as ripping or cross-cutting very large sections of wood. Skip chain also absorbs less power from the motor per unit length of chain than full-complement chain, allowing the use of a longer bar/chain combination on any given motor.
Sources: en.wikipedia.org
=== BrMASS Manuel Riveros Medal === 2024 Livia S. Eberlin, Debora Azevedo 2022 Lidija Nikolaevna Gall, Julia Laskin, Claudia Moraes de Rezende, Rosa Erra-Balsells Maria Fernanda Georgina Gine Rosias Conchetta Cacheres
Commission B1: Thermodynamics and Transfer Processes The objectives of Commission B1 on Thermodynamics and Transfer Processes are to provide academic and industrial information and data, and to propose any solutions on thermodynamics and transfer processes. The Commission B1 has been extremely active in IIR Working Groups, sub-commissions, IIR conferences, co-sponsored conferences, and commission business meetings. As well as being involved in IIR Working Groups on the mitigation of direct emissions of greenhouse gases in refrigeration, the commission is equally involved in the Working Group on Life Cycle Climate Performance (LCCP) Evaluation. Active in IIR conferences and congresses, Commission B1 similarly organises workshops in various fields such as refrigerant charge reduction in refrigerating systems. Initiatives and opportunities, such as the phase-down of high-GWP refrigerants, energy-efficient buildings and cars, transport refrigeration, food preservation, the economic importance of the refrigeration sector, the involvement of the younger generation and identifying industrial needs are all at the heart of Commission B1.
==== Invasion of Iraq ==== Planning for the Operation Iraqi Freedom began in December 2001; in 2002 several teams of 10th SFG and CIA SAD operatives were infiltrated into Iraqi Kurdistan in advance of hostilities. They were based in the Harir valley outside Irbil and tasked to develop ground truth intelligence while organising and training the Peshmerga; they were also there to monitor Ansar al-Islam and plan for a future operation against them. For the 2003 invasion of Iraq, CJSOTF-West (Combined Joint Special Operations Task Force-West/Task Force Dagger) was formed around the 5th SFG, their ODAs were tasked with two core missions: the first – to counter the SCUD TELs and by denying the Iraqi military the use of potential launch sites and the second – provide both intelligence-gathering and screening function in support of conventional forces to build up an accurate picture of Iraqi force dispositions in western Iraq. The Green Beret ODAs were deployed under the command and control of ODBs (Operational Detachment Bravo) which operated as roving AOBs (Advanced Operating Bases), these AOBs provided a mobile resupply function using their modified M1078 Light Medium Transport Vehicles which meant that the ODA patrols could operate for extended periods in enemy territory before linking up with a fighting patrol that would be escorting the AOBs for combat resupply.
==== NIH Toolbox ==== In September 2006, the NIH Blueprint for Neuroscience Research started a contract for the NIH Toolbox for the Assessment of Neurological and Behavioral Function to develop a set of state-of-the-art measurement tools to enhance collection of data in large cohort studies. More than 250 scientists from almost 100 academic institutions contributed to its development. In September 2012, the NIH Toolbox was rolled out to the research community. NIH Toolbox assessments are based, where possible, on Item Response Theory and adapted for testing by computer.
Sources: en.wikipedia.org
=== Analogues === A notable analogue of SDA is 4T-MMDA-2 (2-methoxy-4T-MDA), which was described by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved). Other analogues of SDA include SDMA, MDA, MDMA, 5-APB, 5-APDB, and 6-APBT, among others.
In 2007 a 10-year-old male Dalmatian dog was described with acromegalic signs such as an enlarged tongue and head, widened interdental space, and thickening of skin; along with other signs of hypersomatotropism such as polyphagia, obesity, and stridor. Insulin levels were heightened and the dog had glucose intolerance; however, the dog was not diabetic as blood glucose levels were found to be normal after multiple tests. Levels of IGF-1 and growth hormone were heightened. CT imaging showed a pituitary mass which was later confirmed to be an acidophilic adenoma stained for growth hormone; however, mammary tumour-induced acromegaly is rare with few reported cases. Hypothyroidism can increase levels of growth hormone and IGF-1 in dogs. Some of the physical changes in dogs with hypothyroidism may be due to increased growth hormone concentration.
In a 2013 interview, Forsythe lambasted the "[w]orst script ever written", adding, "basically, I don’t think there was one line from the script that we actually said in the movie." Hasty rewrites were made by Doninger, Cushnir and Harley Peyton based on collective feedback.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.